Clicky

Glaxosmithkline Plc(GSK)

Description: GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.


Keywords: Medicine Biotechnology Pharmaceutical Disease Pharmacy Consumer Infectious Diseases Pharmacology Nutrition Healthcare Products Oncology Inflammation Rare Diseases HIV Skin Respiratory Diseases Smith Consumer Healthcare Consumer Healthcare Products Respirator Axe Infectious Glaxosmithkline Pharmaceuticals Ltd Panacea Biotec

Home Page: www.gsk.com

GSK Technical Analysis

980 Great West Road
Brentford, TW8 9GS
United Kingdom
Phone: 44 20 8047 5000


Officers

Name Title
Ms. Emma Natasha Walmsley CEO & Director
Mr. Iain James Mackay CFO & Exec. Director
Ms. Julie Brown Chief Financial Officer
Ms. Shobie Ramakrishnan Chief Digital & Technology Officer
Mr. Tony Wood Chief Scientific Officer
Ms. Sarah Elton-Farr Head of Investor Relations
Mr. James Ford Sr. VP & Group Gen. Counsel of Legal & Compliance
Ms. Sally Jackson Sr. VP of Global Communications & CEO Office
Ms. Diana Conrad Chief People Officer
Mr. David Simon Redfern Chief Strategy Officer

Exchange: LSE

Country: UK

Currency: Pence sterling (p)

Forward PE: 9.6712
Trailing PE: 12.9339
Price-to-Book MRQ: 6.4589
Price-to-Sales TTM: 1.5768
IPO Date:
Fiscal Year End: December
Full Time Employees: 90096
Back to stocks